Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotransplant(BTRN) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (139)	11/25/1998 9:59:00 AM
From: scaram(o)uche	Respond to of 1475

REAL science (thanks RC.....)....... ex2.excerptamedica.com search by author for Spitzer, T.R. and Sykes, M., and please comply with embargo........ Abstract #2136 - 3:00, Monday, December 7, 1998 - Room D130-131 TRANSPLANTATION - Nonmyeloablative Regimens/Mixed Chimerism MIXED LYMPHOHEMATOPOIETIC CHIMERISM IN ADULT RECIPIENTS FOLLOWING NON-MYELOABLATIVE THERAPY AND HLA-MATCHED OR MISMATCHED DONOR BONE MARROW TRANSPLANTATION, AND THE EFFECT OF DONOR LEUKOCYTE INFUSIONS Abstract #2818 - 4:45, Monday, December 7, 1998 - Room C125 TRANSPLANTATION - Regimen Toxicities and Engraftment II CHARACTERISATION OF PHENOTYPIC AND FUNCTIONAL LYMPHOCYTE RECONSTITUTION IN ADULT PATIENTS WITH CHEMORADIOREFRACTORY HEMATOLOGICAL MALIGANCIES (HM) RECEIVING A NOVEL NON-MYELOABLATIVE CONDITIONING THERAPY AND HLA-MATCHED AND MISMATCHED DONOR BONE MARROW TRANSPLANTATION (BMT) Abstract #2134 - 2:30, Monday, December 7, 1998 - Room D130-131 TRANSPLANTATION - Nonmyeloablative Regimens/Mixed Chimerism INDUCTION OF MIXED CHIMERISM AND POTENT ANTI-TUMOR RESPONSES FOLLOWING NON-MYELOABLATIVE CONDITIONING THERAPY AND HLA-MATCHED AND MISMATCHED DONOR BONE MARROW TRANSPLANTATION (BMT) FOR REFRACTORY HEMATOLOGIC MALIGNANCIES (HM)